Here is how Beam Therapeutics Inc. (BEAM) and Aurora Cannabis Inc. (ACB) have performed compared to their sector so far this year.

The average of price targets set by Wall Street analysts indicates a potential upside of 67.3% in Beam Therapeutics (BEAM). While the effectiveness of this highly sought-after metric is questionable, ...

Has Beam Therapeutics Inc. (BEAM) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that ...

Dr. Barry W. Goy explains how to interpret PSA levels after prostate cancer treatment and how to manage recurrence based on ...

Adding 6 months of neoadjuvant deprivation therapy (NADT) doesn’t seem to add any benefit for patients with intermediate-risk ...

BMO Capital Markets reaffirmed their Outperform rating on Beam Therapeutics Inc (NASDAQ:BEAM), with a steady price target of $57.00. Currently trading at $26.57, the stock appears undervalued ...

On Thursday, Ark Invest, led by Cathie Wood, sold a chunk of its Robinhood shares. The sales come after the company posted ...

Barry Goy, MD, provides insight into the clinical implications of a retrospective analysis examining 15-year outcomes in patients with intermediate-risk prostate cancer.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

An exotic new approach could shrink kilometer-scale machines into table-top devices.